Shares in Zealand Pharma plunged as much as 30% on Friday after the company disclosed Phase II results for its obesity drug candidate petrelintide that were weaker than many investors had anticipated.
The company reported that its ZUPREME-1 Phase II trial in overweight or obese people without type 2 diabetes produced a weight loss of 10.7% at week 42 on an efficacy estimand basis for the highest dose tested. The figure reflects the company-reported outcome for the trial's top dose cohort and serves as the headline efficacy metric provided to the market.
Analyst reactions and market positioning
JPMorgan analyst Sophia Graeff Buhl Nielsen described the result as slightly below expectations. According to the analyst commentary cited by the company, many in the analyst community had been looking for weight loss in the roughly 12% to 15% range to signal a stronger competitive stance versus rival obesity therapies.
Despite noting the shortfall relative to those expectations, the JPMorgan commentary said the Phase II outcome does not preclude a stronger showing in Phase III. The analyst highlighted that trial design changes that raise the share of female participants - who appeared to have experienced larger weight reductions in this study - could help lift observed efficacy toward a mid-teens profile in a later-stage trial.
Jefferies echoed the view that the headline efficacy would likely disappoint investors and exert downward pressure on the stock in the near term. The brokerage pointed out that the 10.7% result fell below its own 13% to 15% expectation and below buy-side hopes for outcomes north of 15%.
Jefferies analyst Lucy Codrington noted the potential for meaningful efficacy while also stressing the drug's strong tolerability. In her note she characterized the profile as having the potential for "Wegovy-like efficacy, but with placebo-like tolerability," adding that this would make petrelintide a viable therapy but one likely regarded as second-best to LLY's elora for now. She cautioned that shares were likely to be sharply down on the announcement even if the profile could preserve some investor hope over time.
Tolerability and dose differentiation
Codrington emphasized petrelintide's favourable tolerability profile. She pointed to the highest-dose group in ZUPREME-1, which showed no vomiting and low levels of other gastrointestinal side effects. That safety profile led her to suggest the drug has a role, even if the efficacy results complicate positioning it as best-in-class at this stage.
The trial data also suggested limited separation among the top dose groups, with weight reductions ranging roughly between 10.2% and 10.7% across those cohorts. JPMorgan interpreted that pattern as a signal that further dose escalation might offer only marginal incremental benefit.
Detailed study data are scheduled to be presented at a scientific conference later this year, the company said. Until the full dataset is available, analysts and investors will be evaluating whether changes in trial design or population mix could materially alter the drug's efficacy profile in Phase III.
Implications for markets and sectors
The announcement had immediate market impact, driving a sharp share-price reaction for the biotech. The news is relevant for investors focused on biotechnology and pharmaceuticals, and for market participants tracking the competitive landscape among obesity therapies. It also touches on the healthcare sector more broadly given the ongoing interest in new obesity treatments and their commercial prospects.